Analyzing the Role of Second-Line Ramucirumab in HCC
Ghassan K. Abou-Alfa, MD, discusses the current role for ramucirumab for the treatment of patients with hepatocellular carcinoma in the second-line setting.
Ghassan K. Abou-Alfa, MD, from the Memorial Sloan Kettering Cancer Center, discusses the current role for ramucirumab (Cyramza) for the treatment of patients with hepatocellular carcinoma (HCC) in the second-line setting.
In May 2019, theFDA granted approval to ramucirumab monotherapy for the treatment of patients with HCC who have an alpha-fetoprotein (AFP) level of ≥400 ng/mLand have been previously treated with sorafenib (Nexavar), based on data from the phase III REACH-2 trial. For now, this agent is only applicable to patients with an elevated AFP above 400, says Abou-Alfa, but elevated AFP levels remain a complex piece of information.
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
